13-Ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol

Base Information

• Chemical Name: 13-Ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
• CAS No.: 53016-31-2
• Molecular Formula: C21H29 N O2
• Molecular Weight: 327.46
• Hs Code.: 2937230000
• European Community (EC) Number: 642-893-5
• Wikipedia: Norelgestromin
• Wikidata: Q15295638
• NCI Thesaurus Code: C66243
• RXCUI: 326374
• Mol file: 53016-31-2.mol

Synonyms:Norelgestromin;53016-31-2;17-Deacetylnorgestimate;FT-0665916

Chemical Property of 13-Ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol

Chemical Property:

• Vapor Pressure: 9.76E-12mmHg at 25°C
• Melting Point: 107-109°C
• Boiling Point: 491.9°Cat760mmHg
• PKA: 12.22±0.60(Predicted)
• Flash Point: 327.1°C
• PSA: 52.82000
• Density: 1.23g/cm³
• LogP: 4.14370
• Storage Temp.: Refrigerator
• XLogP3: 3.6
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 2
• Exact Mass: 327.219829168
• Heavy Atom Count: 24
• Complexity: 642

Purity/Quality:

98%Min ^*data from raw suppliers

(E/Z)-17-Deacetylnorgestimate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=NO)CCC34
• Recent ClinicalTrials: A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.
• Recent EU Clinical Trials: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women
• Description: Ortho Evra@ is the first birth control transdermal patch and contains a combination of norelgestromin and ethinylestradiol. The patch can be applied to the buttocks, lower abdomen, upper torso or arms; changed weekly for 3 weeks, followed by a patch-free week. Norelgestromin is the active metabolite produced following oral administration of norgestimate, the progestin component of the contraceptive, Ortho-Cyclen?. The half-life value of norelgestromin was approximately 28 h. Following application, norelgestromin rapidly appeared in the serum, reached a plateau by approximately 48h and was maintained at an approximate steady state throughout the wear period. Hepatic metabolites of norelgestromin included norgestrel and various hydroxylated and conjugated metabolites that were eliminated by renal and fecal pathways. Ortho Evra produced ovarian suppression and cycle control. It was significantly more effective in suppressing follicular development than the leading oral contraceptive Triphasil? (ethinyl estradiol/levomorgestrel); was as effective in preventing pregnancies and had similar tolerability profile. The patch offers 99% efficacy when used appropriately, as shown by three clinical trials. However, a statistically significantly greater proportion of pregnancies occurred among women weighing 90 kg or more. Ortho Evra? was well tolerated, with 2.6% of women discontinuing treatment due to mild to moderate reactions at the site of application. Thus, the patch combined the efficacy of oral contraceptives with the convenience of just once-weekly dosing.
• Uses: E/Z-17-Deacetylnorgestimate is a metabolite of Norgestimate. A contraceptive for birth control used by women. A metabolite of Norgestimate